$3.99
1.27%
Nasdaq, Aug 29, 11:51 pm CET
ISIN
US17248W3034
Symbol
CING

Cingulate Stock price

$3.99
-1.17 22.67% 1M
-0.13 3.16% 6M
-0.94 19.07% YTD
-2.44 37.95% 1Y
-435.21 99.09% 3Y
-1,064.01 99.63% 5Y
-1,064.01 99.63% 10Y
-1,064.01 99.63% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
+0.05 1.27%
ISIN
US17248W3034
Symbol
CING
Industry

Key metrics

Basic
Market capitalization
$21.6m
Enterprise Value
$17.8m
Net debt
positive
Cash
$8.9m
Shares outstanding
4.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.9
Financial Health
Equity Ratio
50.2%
Return on Equity
-208.5%
ROCE
-264.8%
ROIC
-
Debt/Equity
0.9
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-17.2m | -
EBIT
$-17.8m | $-13.5m
Net Income
$-18.0m | $-16.1m
Free Cash Flow
$-17.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
4.7% | -
EBIT
4.6% | 13.8%
Net Income
6.0% | -3.2%
Free Cash Flow
1.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-4.1
FCF per Share
$-3.6
Short interest
3.7%
Employees
13
Rev per Employee
$0.0
Show more

Is Cingulate a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Cingulate Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Cingulate forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Cingulate forecast:

Buy
90%
Hold
10%

Financial data from Cingulate

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.17 7.17
17% 17%
-
- Research and Development Expense 11 11
15% 15%
-
-17 -17
5% 5%
-
- Depreciation and Amortization 0.64 0.64
2% 2%
-
EBIT (Operating Income) EBIT -18 -18
5% 5%
-
Net Profit -18 -18
6% 6%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cingulate directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cingulate Stock News

Neutral
GlobeNewsWire
14 days ago
Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301 Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026
Neutral
GlobeNewsWire
18 days ago
Jennifer Callahan, Chief Financial Officer, appointed Interim CEO Board member, Jay Roberts appointed Executive Chairman KANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CING) The Board of Directors of Cingulate Inc. (“Cingulate”) announced that it has placed Chairman and Chief Executive Officer, Shane J.
Neutral
GlobeNewsWire
27 days ago
Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients
More Cingulate News

Company Profile

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in 2013 and is headquartered in Kansas City, KS.

Head office United States
CEO Shane Schaffer
Employees 13
Founded 2013
Website www.cingulate.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today